Latest Updates
-
OTT Releases This Week (October 19–25): New Movies And Series On Netflix, Prime Video, JioHotstar And Zee5 -
Police Commemoration Day 2026: Know The History, Significance And Programmes Planned Across India This Year -
Deepika Padukone And Ranveer Singh Announce Second Daughter’s Name On Dussehra, Share Family Photo -
Who Was Karthik Sabesh? Tamil Actor Passes Away At 37, Days After Uncle And Composer Deva’s Death -
Who Is Ravleen Varghese? Meet The First Malayali Model To Walk The Victoria’s Secret Runway -
World Osteoporosis Day 2026: A Minor Fall, A Major Fracture — Doctor On Why Older Adults Should Be Careful -
Durga Visarjan 2026: October 20 or 21? Know Shubh Muhurat, Rituals And Significance -
Happy Dussehra 2026: 50+ Wishes, Messages And Greetings To Share With Family And Friends -
Dussehra 2026: Astrologer Ashutosh Clairvoyant On Colours, Offerings And Puja Rituals For Each Zodiac Sign -
Hustle Culture Has a Bedroom Problem No One Talks About, Expert Explains
DCGI Approves India's First qHPV Vaccine Against Cervical Cancer
Update: As per recent news reports, the DCGI subject expert committee has approved Serum Institute's indigenously created qHPV vaccination for cervical cancer. It will be India's first indigenous cervical cancer vaccine.

Serum Institute of India (SII) has applied to the country's drug regulator seeking market authorisation to manufacture indigenously developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said on Wednesday, June 8.
The Pune-based firm has applied for market authorisation after completing the phase 2/3 clinical trial with support of the Department of Biotechnology to ensure its early availability in the country, they said.
In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, director (government and regulatory affairs) at SII, said the vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
The SII is also learnt to have made a presentation before the working group of HPV under the chairmanship of Dr NK Arora constituted separately by the NTAGI to review the data and usefulness of this vaccine on Wednesday, the sources said.

In the application, Singh mentioned that every year lakhs of women are diagnosed with cervical cancer as well as few other cancers and death ratio is also very high.
Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.
"Also, it is noteworthy that presently, our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group & under the leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high quality 'Made in India' vaccines at an affordable price for people of our country and the world at large," Singh said in the application.
"Like many other indigenous life-saving vaccines, we are committed to making our country 'ATMANIRBHAR' for India's first indigenous life-saving qHPV vaccine also. This will fulfill the dream of our Hon'ble Prime Minister Narendra Modi 'VOCAL FOR LOCAL' and 'MAKING IN INDIA FOR THE WORLD' and will ensure the prevention of cancers caused by Human Papillomavirus (Type 6, 11, 16 & 18) vaccine recombinant," Singh is learnt to have said in the application.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications
